Organogenesis ORGO
1.41
(0.01)
(0.70%)
as of 25 Sep
- Market cap
- $207.1M
- P/E
- 0.0×
Follow ORGO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 57.56 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.68 | 0.59 | 1.16 | 1.15 | |
P/FCF ratio |
15.00 | 17.73 | 0.00 | 0.00 | |
P/Operating CF |
(9.88) | 14.34 | 16.65 | 173.90 | |
P/B ratio |
2.11 | 1.24 | 2.19 | 2.10 | |
Price to Tangible BV |
2.68 | 1.43 | 2.50 | 2.47 | |
EV/Sales |
0.62 | 0.45 | 1.03 | 1.03 | |
EV/EBITDA |
0.00 | 6.44 | 8.11 | 26.66 | |
EV/Operating CF |
8.84 | 7.45 | (56.35) | (12.35) | |
EV/FCF |
13.56 | 13.41 | (23.75) | (9.28) | |
Quick Ratio |
2.59 | 2.75 | 3.11 | 2.58 | |
Current Ratio |
3.52 | 3.53 | 3.62 | 3.32 | |
Net Debt/EBITDA |
0.81 | 1.41 | (1.16) | (2.25) | |
Debt/Assets |
2.66% | 2.38% | 2.14% | 0.41% | |
Debt/Equity |
0.07 | 0.05 | 0.04 | 0.01 | |
Asset Turnover |
1.05 | 1.04 | 1.03 | 0.97 | |
Operating CF/Net income |
0.32 | (0.38) | 1.00 | 0.21 | |
Capex/Depreciation |
(0.17) | (0.25) | (0.66) | (0.32) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
41.82% | 40.72% | 4.56% | 8.76% | |
Selling, General and Administrative Expense of Revenue |
123.33% | 175.10% | 44.40% | 52.86% | |
Intangible Assets out of Total Assets |
0.08 | 0.06 | 0.06 | 0.08 | |
Share Based Compensation of Revenue |
6.98% | 9.77% | 1.92% | 2.03% | |
Graham Net Nets |
(0.19) | (0.02) | 0.10 | 0.08 | |
Graham Number |
0.00 | 0.00 | 2.19 | 0.00 | |
Earnings Yield |
(34.98%) | (7.59%) | 1.74% | (2.61%) | |
Free Cash Flow Yield |
6.66% | 5.64% | (3.73%) | (9.65%) | |
Revenue per Share |
0.34 | 0.29 | 1.78 | 1.19 | |
Operating CF per Share |
(0.25) | 0.17 | 0.31 | 0.02 | |
Capex per Share |
(0.01) | (0.02) | (0.04) | (0.02) | |
Free Cash Flow per Share |
(0.25) | 0.14 | 0.27 | 0.01 | |
Cash per Share |
0.36 | 0.72 | 0.74 | 0.51 | |
Shareholders Equity per Share |
1.15 | 1.91 | 2.37 | 2.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.15 | 1.91 | 2.37 | 2.01 | |
Free Cash Flow |
(32.75) | 17.98 | 34.77 | 0.84 | |
Working Capital |
143.34 | 192.48 | 262.06 | 209.43 | |
Capital Expenditures |
(1.10) | (3.15) | (4.65) | (2.23) | |
Net Current Asset Value |
(57.88) | (6.94) | 63.59 | 45.05 | |
EV/EBIT |
0.00 | 89.88 | 13.00 | 0.00 | |
Capex to Sales |
0.03 | 0.08 | 0.02 | 0.01 | |
Net Profit Margin |
(227.03%) | (150.85%) | 17.42% | 9.63% | |
Price to Operating Income |
0.00 | 118.82 | 14.69 | 0.00 | |
| Other line items | |||||
Average Receivables |
110.66 | 110.11 | 163.66 | 135.03 | |
Average Payables |
29.51 | 26.64 | 30.43 | 32.10 | |
Average Inventory |
31.16 | 28.88 | 27.92 | 33.31 | |
Average Assets |
433.79 | 493.69 | 548.31 | 478.06 | |
Average Common Equity |
190.76 | 243.73 | 281.51 | 266.84 |
Columns are period end dates